SAN DIEGO and SUZHOU, China, April  02, 2026  (GLOBE NEWSWIRE) -- Adagene Inc. (&#34;Adagene&#34; or the &#34;Company&#34;) (NASDAQ:ADAG), a company committed to transforming the discovery and development of novel antibody-based

ADAG

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

Adagene to Raise Approximately $70 Million Through Public Offering

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN DIEGO and SUZHOU, China, April  02, 2026  (GLOBE NEWSWIRE) -- Adagene Inc. (&amp;#34;Adagene&amp;#34; or the &amp;#34;Company&amp;#34;) (NASDAQ:ADAG), a company committed to transforming the discovery and development of novel antibody-based</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Adagene has announced a public offering priced at $3.75 per ADS, expected to raise around $70 million. The offering, featuring participation from both new and existing investors, is set to close on April 6, 2026, and may enhance the company&#039;s capital for ongoing innovations in cancer therapies.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Adagene priced a public offering of 18.67 million ADSs at $3.75 each.</li><li>Gross proceeds expected to be around $70 million before expenses.</li><li>Offering closes on April 6, 2026, pending customary conditions.</li><li>Participation includes both new and existing institutional investors.</li><li>Adagene&#039;s focus remains on antibody-based therapies for cancer treatment.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Leerink Partners (N/A)</strong>: Joint book-runner for the offering, indicating strong underwriting support.</li><li><strong>LifeSci Capital (N/A)</strong>: Co-manager for the offering, contributing to its credibility.</li><li><strong>Janus Henderson Investors (JHG)</strong>: A major investor participating in the offering, signaling confidence in ADAG.</li><li><strong>Deerfield Management (N/A)</strong>: Participating investor, reflecting institutional support for Adagene.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>The news fits under &#039;Corporate Developments&#039; as it announces a significant public offering that may influence Adagene&#039;s capital structure and strategic initiatives. This capital influx is crucial for ongoing and future projects in the biotech landscape, particularly in antibody therapies.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Adagene&#039;s offering price matches the 30-day VWAP, indicating strong market confidence.</li><li>The estimated proceeds could significantly bolster its R&amp;D efforts in antibody therapies.</li><li>Institutional backing from prominent investors may enhance stock stability.</li><li>Successful closing of the offering could prompt a positive momentum in share price.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Adagene is offering 18,666,000 ADSs at $3.75 per share.</li><li>Expected proceeds are approximately $70 million.</li><li>Closing of the offering is anticipated on April 6, 2026.</li><li>Adagene utilizes AI and computational biology for novel antibody designs.</li><li>The company has strategic collaborations leveraging its SAFEbody technology.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>ADAG could experience upward momentum short-term, with increased liquidity supporting future growth.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">SAN DIEGO and SUZHOU, China, April  02, 2026  (GLOBE NEWSWIRE) -- Adagene Inc. ("Adagene" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ADAG">ADAG</a>), a company committed to transforming the discovery and development of novel antibody-based therapies, today announced the pricing of its underwritten public offering of 18,666,000 American depositary shares, or ADSs, each representing 1.25 ordinary shares of the Company, par value US$0.0001 per share, at the offering price of US$3.75 per ADS, representing the 30-day volume-weighted average price ("VWAP").</p>  <p align="justify">The gross proceeds to Adagene from the offering are expected to be approximately US$70.0 million, before deducting underwriting discount and offering expenses. The offering is expected to close on April 6, 2026, subject to the satisfaction of customary closing conditions.</p>  <p align="justify">Leerink Partners and LifeSci Capital are acting as joint book-running managers for the offering. Lucid Capital Markets is acting as co-manager for the offering.</p>  <p align="justify">The offering featured participation from new and existing investors including Janus Henderson Investors, Deerfield Management, Invus, Sirenia and Columbia Threadneedle Investments, among others.</p>  <p align="justify">The offering is being made pursuant to a shelf registration statement on Form F-3, including a base prospectus, that was initially filed with the Securities and Exchange Commission (SEC) on May 9, 2025 and became effective on May 30, 2025. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available for free on the SEC's website located at <a href="https://www.globenewswire.com/Tracker?data=HR6euKpQ3ZIlBG9XT6d26CaJjs-I4hgjDUo_ciAU9r5IwZuJ3b0pda93OAaSdp3q9NkXn58WuDGSPCKvYG6IuZjxTjOKev_tRgp3Gn1D-U7tIASiT8zD2bv-qcitsIQjs1PAkz8E8-sR12D3ZUG3yhVbs5CoG3mS1IuOXCl_nGmoyTsMietNUIYw-Sp7JpIxyNys4TNmY7aBJfpXiJBG-MxDf5BjAU6baJBGiMJ6118=" rel="nofollow" target="_blank">www.sec.gov</a>. Copies of the prospectus relating to the offering may be obtained, when available, from: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; or LifeSci Capital LLC, 1700 Broadway, 40th Floor, New York, New York 10019, or by email at <a href="mailto:legalnotices@lifescicapital.com">legalnotices@lifescicapital.com</a>.</p>  <p align="justify">This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>  <p align="justify"><strong>About Adagene Inc.</strong></p>  <p align="justify">Adagene Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/ADAG">ADAG</a>) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address globally unmet patient needs. The company has forged strategic collaborations with reputable global partners that leverage its SAFEbody precision masking technology in multiple approaches at the vanguard of science.</p>  <p align="justify"><strong>Safe Harbor Statement</strong></p>  <p align="justify">This press release contains forward-looking statements, including, but not limited to, statements relating to the satisfaction of customary closing conditions related to the offering, the expected closing of the offering and the anticipated gross proceeds from the offering and Adagene's intended use of the net proceeds therefrom. Actual results may differ materially from those indicated in the forward-looking statements due to the risks and uncertainties associated with market conditions and the satisfaction of customary closing conditions related to the offering, as well as risks and uncertainties inherent in Adagene's business described in the Company's prior press releases as well as those risks more fully discussed in the "Risk Factors" section in Adagene's filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.</p>  <p><strong>Investor Contacts:</strong></p>  <p>Raymond Tam<br></br><a href="https://www.globenewswire.com/Tracker?data=RkqWZAcXBB4w6DNUMh5IPqHdTsTcyTx4odznobukF0TwFi6JajrSBfILi1jIiPk05EyHj1izPo--DuL7Vlx1J8sTPTdn_g8zL7xY-y5CUW9I3gyyWBkGILmv3iRMSf_X" rel="nofollow" target="_blank">raymond_tam@adagene.com</a></p>  <p>Corey Davis<br></br>LifeSci Advisors<br></br><a href="https://www.globenewswire.com/Tracker?data=KxhkzhHHsrM6mxaBRaF6Zc29Ev_6J9h4I7CZdMMSBYL1f5ItNiD2AX0uYBoCdbhj5TcbLHKguhV_WXfkIdKiOgXPFr0mUpcpEnk-rrXfXpJeODoPwcXNEAiTUILN7tyw" rel="nofollow" target="_blank">cdavis@lifesciadvisors.com</a></p>  <p><strong>Media Contact:</strong><br></br>Lindsay Rocco<br></br>Elixir Health PR<br></br>862-596-1304<br></br><a href="https://www.globenewswire.com/Tracker?data=1u--K6YwnejWAcF3usu4gfm7vYBNaoEwgpwfrlLyPVRqY20LjcBjZITX7y9seZHaJb-bu020Mnem5BVDUViNz0E6wf4CiQdmEPOaSG9MuWJu89fsimZzfAHolZeuXxCF" rel="nofollow" target="_blank">lrocco@elixirhealthpr.com</a></p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY4MzI3MSM3NTE3MTc1IzIyMDQ2ODE="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/M2U1MjY4MDctOTkwZS00OWJkLTg0MDMtYTE1ODM1ZTkyNjFkLTEyMTYyMzQtMjAyNi0wNC0wMi1lbg==/tiny/Adagene-Inc-.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/c377318b-edf7-42c0-8e7c-63a02bbe47b0"><img src="https://ml.globenewswire.com/media/c377318b-edf7-42c0-8e7c-63a02bbe47b0/small/adagene-logo-gnw-png.png" border="0" width="150" height="132" alt="Primary Logo"></img></a></p>

Adagene has announced a public offering priced at $3.75 per ADS, expected to raise around $70 million. The offering, featuring participation from both new and existing investors, is set to close on April 6, 2026, and may enhance the company's capital for ongoing innovations in cancer therapies.

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News